Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Polyphor
Polyphor
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
Polyphor and Wellcome Trust to develop novel antibiotics against multi-drug resistant Gram-negative pathogens
Final milestone reached ahead of schedule triggering payment of a CHF 0.97 million convertible loan amount
Research & Development
Kalina Scott appointed new CFO of Polyphor
Research & Development
New hope against antibiotic resistance: Outer-Membrane Protein Targeting Antibiotics
OMPTA platform could bring further new important therapies in the treatment of Gram-negative pathogens
Recruitment
Debra Barker appointed as new CMDO of Polyphor
Polyphor has announced the appointment of Dr Debra Barker, MD and MSc, to the role of Chief Medical and Development Officer (CMDO)
Research & Development
Polyphor appoints Michael Altorfer as Chief Executive
He replaces Jean-Pierre Obrecht, who will continue as a member of the Board of Directors
Research & Development
Roche signs licensing agreement with Polyphor to combat multi-drug resistant infections
Makes an upfront payment of CHF35m to Polyphor in deal that could be worth up to CHF500m
Research & Development
Polyphor signs MacroFinder collaboration with Boehringer Ingelheim
Will use technology to identify drug candidates addressing therapeutic targets chosen by BI
Subscribe now